News for Apellis Pharmaceuticals, Inc. (APLS)

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. (APLS) has announced a significant addition to its Board of Directors with the appointment of Craig Wheeler. Wheeler, who brings o

Apellis Pharmaceuticals (APLS) appoints Craig Wheeler to its Board of Directors, effective immediately. Craig Wheeler has extensive experience in the bi

Summary On April 21, 2025, Apellis Pharmaceuticals Inc (APLS) announced the appointment of Craig Wheeler, founder and CEO of Headwaters Biotech Advisors, to its

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ( APLS) today announced that Craig Wheeler, founder and chief executive offic

**media[600295]**

Bank of America has adjusted its price target for Apellis Pharmaceuticals (APLS), bringing it down to $41 from the previous $44. Despite this revision, the inve

Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.

On March 24, 2025, EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, made a strategic move by increasing its stake in Zymeworks Inc (ZYME). T

On March 13, 2025, EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, made a significant move by acquiring an additional 1,081,980 shares of Z

/PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, will host the 14th Annual Prevent Blindness Focus...

Discover how Apellis Pharmaceuticals, Inc. surpasses Q4 expectations with impressive revenue growth and cost reductions. Click for my APLS earnings update.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ETCompany ParticipantsCedric Francois - Co-Founder...

The following slide deck was published by Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript February 28, 2025Apellis Pharmaceuticals, Inc. beats earnings expectations.

Total Revenue (Q4 2024): Approximately $213 million.SYFOVRE Revenue (Q4 2024): $168 million in US net product revenue.EMPAVELI Revenue (Q4 2024): $23 million i

Apellis Pharmaceuticals Inc faces significant competition in its key markets, which may impact its market share and profitability.The company has incurred sign

Feb 28, 2025 / 01:30PM GMTOperator Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and